About UCSF Search UCSF UCSF Medical Center

Sabrina M. Ronen, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ronen_sabrina

Professor in Residence, Department of Radiology, UCSF

sabrina.ronen@radiology.ucsf.edu

Phone: (415) 514-4839 (voice)
Box 2532, UCSF
San Francisco, CA 94143-2532

View on UCSF Profiles


Additional Websites


Education

Hebrew University, Israel, BSc, 1981, Chemistry/Biochemistry
San Jose State University, California, MS, 1986, Chemistry
Weizmann Institute of Science, Israel, PhD, 1991, Chemical Physics


Professional Experience

  • 1978-1981
    Laboratory Assistant, Hebrew University, Biochemistry Department, Israel
  • 1981-1984
    Assistant Staff, Raychem Corporation, Polymer Manufacturing R&D, Menlo Park, California
  • 1985-1986
    M.Sc., student, San Jose State University, San Jose, California
  • 1987-1992
    Ph.D., student, Weizmann Institute of Science, Israel
  • 1992-1994
    INSERM Poste Vert Visiting Researcher, Institut Curie, Cancer Research Inst., Paris, France
  • 1994-1996
    British Heart Foundation Fellow, Harefield Hospital Nephrology Department, Harefield, UK
  • 1996-2003
    ICR fellow and leader, Pre-clinical Cellular Processes Team, CRUK Clinical Magnetic Resonance Research Group, Institute of Cancer Research Sutton, Surrey, UK
  • 2004-2007
    Associate Professor, Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas
  • 2007-2012
    Associate Professor, Department of Radiology, UCSF, San Francisco, California
  • 2012-present
    Professor in Residence, Department of Radiology, UCSF, San Francisco, California

Honors & Awards

  • B.Sc. cum laude
  • Recipient of the Eshkol scholarship for Ph.D. studies
  • Recipient of an ICR fellowship (first three years at Institute at Institute of Cancer Research, UK)
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary Elect 2006
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary 2007

Selected Publications

  1. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One. 2013; 8(5):e62351.
    View on PubMed
  2. Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM. HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One. 2013; 8(4):e62610.
    View on PubMed
  3. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013; 8(2):e57610.
    View on PubMed
  4. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013 Apr 1; 19(7):1773-83.
    View on PubMed
  5. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013; 4:2429.
    View on PubMed
  6. Lodi A, Woods SM, Ronen SM. Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed. 2013 Mar; 26(3):299-306.
    View on PubMed
  7. Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul; 70(1):33-9.
    View on PubMed
  8. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61.
    View on PubMed
  9. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25.
    View on PubMed
  10. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed. 2012 Jun; 25(6):843-51.
    View on PubMed
  11. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011 Dec; 11(12):835-48.
    View on PubMed
  12. Lodi A, Ronen SM. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One. 2011; 6(10):e26155.
    View on PubMed
  13. Su JS, Woods SM, Ronen SM. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed. 2012 Feb; 25(2):379-88.
    View on PubMed
  14. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 2012 Jan 2; 59(1):193-201.
    View on PubMed
  15. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011 Jun; 33(6):1284-90.
    View on PubMed
  16. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011 Jan 15; 22(2):165-78.
    View on PubMed
  17. Brandes AH, Ward CS, Ronen SM. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res. 2010; 12(5):R84.
    View on PubMed
  18. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, Wang C, Zhang X, Vigneron DB, Ronen SM. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 2010 Oct 1; 70(19):7400-10.
    View on PubMed
  19. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun; 12(6):559-69.
    View on PubMed
  20. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010 Feb 15; 70(4):1296-305.
    View on PubMed

Go to UCSF Profiles, powered by CTSI